Back to Journals » Drug Design, Development and Therapy » Volume 7

A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

Authors Eligar VS, Bain SC

Received 14 May 2013

Accepted for publication 29 June 2013

Published 30 August 2013 Volume 2013:7 Pages 893—903

DOI https://doi.org/10.2147/DDDT.S32331

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Vinay S Eligar,1 Stephen C Bain2

1University Hospital of Wales, Cardiff, UK; 2Singleton Hospital, Swansea University, Swansea, UK

Abstract: Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease.

Keywords: sitagliptin, CKD, chronic kidney disease, renal impairment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]